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Abstract
Background: Niemann-Pick disease type C (NPC) is a lysosomal storage disease with a heterogeneous
neurodegenerative clinical course. Multiple therapies are in clinical trials and inclusion criteria are currently mainly
based on age and neurological signs, not taking into consideration differential individual rates of disease progression.
Results: In this study, we have evaluated a simple metric, denoted annual severity increment score (ASIS), that
measures rate of disease progression and could easily be used in clinical practice. We show that ASIS is stable over
several years and can be used to stratify patients for clinical trials. It achieves greater homogeneity of the study cohort
relative to age-based inclusion and provides an evidence-based approach for establishing inclusion/exclusion criteria.
In addition, we show that ASIS has prognostic value and demonstrate that treatment with an experimental therapy -
acetyl-DL-leucine - is associated with a reduction in ASIS scores.
Conclusion: ASIS has the potential to be a useful metric for clinical monitoring, trial recruitment, for prognosis and
measuring response to therapy.
Keywords: Niemann-Pick disease type C, NPC, Annual severity increment score, ASIS, Clinical severity scale, Clinical
trials, Experimental therapy, Acetyl-DL-leucine, Tanganil
Background
Two major challenges when performing clinical trials in
rare diseases are low numbers of patients and a high degree
of clinical heterogeneity. Therefore, trials risk being statisti-
cally underpowered due to differential responses to therapy
in a small, heterogeneous group of patients. Current inclu-
sion criteria are predicated frequently on age and clinical
severity rather than on comparable rates of disease progres-
sion. New approaches to patient stratification for clinical
trial recruitment are therefore needed, to improve clinical
trial design and aid the interpretation of trial outcomes.
A rare disease with one approved therapy (miglustat)
[1–3] and multiple therapies in clinical trials is
Niemann-Pick disease type C (NPC) (OMIN 257220).
NPC is a lysosomal storage disorder with a current esti-
mated incidence of approximately 1:100,000 live births
although it might be more common in adults than previ-
ously thought [4]. It is a progressive neurodegenerative
disease for which clinical scoring systems have been
extensively studied and validated [5, 6]. The substrate
reduction therapy drug miglustat is currently the only
approved therapy and is available in most countries
world-wide, with the exception of the USA. Approval
was based on a positive outcome in a non-comparative
international clinical trial conducted on 29 NPC patients
[3]. Therapies currently or recently in clinical trials in-
clude the HSP70 inducer arimoclomol [7]; intrathecal
* Correspondence: m.cortina@ucl.ac.uk; frances.platt@pharm.ox.ac.uk
1Population, Policy and Practice Programme, UCL Great Ormond Street
Institute of Child Health, London WC1N 1EH, UK
2Department of Pharmacology, University of Oxford, Oxford OX1 3QT, UK
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Cortina-Borja et al. Orphanet Journal of Rare Diseases  (2018) 13:143 
https://doi.org/10.1186/s13023-018-0880-9
cyclodextrin (VTS-270 2, hydroxypropyl-beta-cyclodextrin)
[8], intravenous cyclodextrin (TrapsolCyclo®) and the his-
tone deacetylase inhibitor vorinostat [9]. Inclusion criteria
for these trials were differentially based on age and clinical
signs ( [3], NCT02612129, NCT02534844, NCT02124083).
We previously conducted a prospective international
study validating relative lysosomal volume as a bio-
marker in circulating B cells from over 100 NPC patients
[10]. During the data analysis of the study cohort we
identified and characterised six clinical subgroups of
NPC patients that differed in their rates of disease pro-
gression [10]. The level of disability was assessed in that
study using a NPC composite clinical severity score
(NPC-CSS) based on multiple neurological subdomains
(nine major, eight minor) [5]. Some of the domains are
more difficult to evaluate in a comparable fashion be-
tween clinical centres due to the requirement for com-
plex examinations (e.g. auditory brain stem response
(ABR) that may require anaesthesia in young children).
How the total severity score accrues over time reflects
the rate of disease progression.
To analyse subgroups of patients with differential rates
of disease progression, we developed a metric (denoted
annual severity increment score (ASIS)), obtained by
dividing the total severity score by the age of the patient
providing a measure of the rate of disease progression in
individual patients [10]. The resulting value serves as an
index of the annual rate of disease progression. We
speculated [10] that ASIS could be a potential tool for
stratifying patients for clinical trials as it would allow the
clinical cohort to be selected such that within a period
of the trial (typically 1 year) patients left untreated
would have increased their clinical severity score to a
measurable and predictable extent, enabling measure-
ment of potential clinical efficacy of drugs in trials. Fur-
thermore, the patients whose disease is particularly
severe or extremely mild could be excluded from a trial,
using an evidence-based approach, resulting in a more
homogeneous sample within the clinical trial cohort.
ASIS could also be used to ensure greater equality in
assigning patients to different treatment groups in a trial in
terms of a pre-stratification. Furthermore, ASIS could facili-
tate post-hoc analyses to discriminate responders from
non-responders, based on the individual progression rates.
A pre-requisite for ASIS to be useful for stratification
purposes is that the ASIS score of a given patient re-
mains relatively constant over a prolonged period of
time, reflecting a stable rate of disease progression. To
test this hypothesis, we have taken advantage of part of
the study cohort previously collected [10], but added
further longitudinal data points spanning an additional
three years. This provided us with a new data set with
which we could determine how stable individual rates
of progression are over several years and explore the
utility of ASIS as a monitoring, recruitment and prog-
nostic tool.
We found that the majority of patients do indeed have
stable ASIS scores over several years. In addition, by apply-
ing differential ASIS cut-off points, trial cohorts could be
stratified to obtain a more homogeneous patient population
that, if untreated, would change in clinical score within the
typical period of a clinical trial. We have modelled the use
of standard inclusion criteria using three real life clinical
trials and show that ASIS ensures greater clinical homogen-
eity. We also present evidence of ASIS’s potential prognos-
tic value for the majority of NPC patients. We further
investigated whether individual subdomains or combina-
tions of selected subdomains would correlate with the full
neurological composite score. This would address the ques-
tion of whether fewer tests are adequate for an accurate
prediction of the patients’ individual progression. The use
of a small number of subdomains has the potential to make
the testing less burdensome to clinicians, and to patients
and their caregivers. Finally, we applied ASIS to quantify
the slowing of the rate of disease progression in NPC pa-
tients treated with Acetyl-DL-Leucine, an experimental dis-
ease modifying therapy [11].
Methods
Clinical study cohort and ethical approval
Thirty-eight patients from two independent international
clinical cohorts were studied: 13 from the UK (Manchester)
and 25 from Germany (Mainz). They represent a subset of
patients from the cohort we previously analysed [10]. In the
current study, additional longitudinal data were collected.
Research on data obtained from NPC patients were covered
by REC/IRB approvals 06/MRE02/85 (UK) and S-032/2012
(Germany). Written informed consent, and if applicable,
assent, were obtained in each centre. The NPC-CSS used
was the NIH clinical severity scale minus hearing, as hear-
ing was not measured in both centres so was excluded from
the analysis [12]. The higher the severity score, the greater
the disease burden. The maximum clinical score using this
scale for the eight major domains measured (eye move-
ment, ambulation, memory, speech, swallowing, fine motor
skills, cognition and seizures [5]) would therefore be 40.
Minor domains (cataplexy, behavioural changes, narcolepsy,
psychiatric symptoms, hyperreflexia, incontinence, ABR
and respiratory signs) were also included, which each had a
maximal score of 2. The maximum total severity score a
patient could theoretically achieve would therefore be 56
(without hearing). Clinical assessments were conducted by
different individuals in the two centres.
Questionnaire responses
To determine which clinical subdomains related most
closely to patient quality of life we conducted two sur-
veys. Firstly, we asked 22 parents caring for a child with
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NPC (age range of affected child < 1–18 years) and 15
adults with NPC (> 18 years) to answer the following
question; “Please rate the following symptoms of NPC in
order of impact from 1-9, with 1 having the most impact
and 9 the least”. In addition, we asked 16 NPC expert phy-
sicians to answer the following question; “Please mark the
six domains in the NPC clinical severity scale that in your
opinion are of most clinical relevance to the patient”.
Statistical methods
Chi-squared test was used to compare proportions,
Wilcoxon-Mann-Whitney and Kruskal-Wallis tests to
compare locations and Ansari-Bradley test to compare
dispersions. Correlation was assessed using Spearman’s
rank correlation coefficient. Goodness-of-fit was evalu-
ated using the maximum absolute deviation (MAD)
from the model’s predictions. Nonparametric kernel
density estimators were obtained using a Gaussian ker-
nel with bandwidth selected using Silverman’s rule [13].
We used Friedman’s locally adaptive smoother to repre-
sent data-driven joint variations in scatterplots [14]. To
assign relative rank order to clinical subdomains ques-
tionnaire responses, individual responses were summed
and placed in ascending order with 1 being the most im-
portant and 9 the least important. All calculations were
performed in the R language and environment for statis-
tical computing (http://www.R-project.org) version 3.2.2.
Acetyl-DL-Leucine treatment of NPC patients
Ten NPC patients (not part of the main study cohort)
from Germany and Slovakia (2 females, mean age
(standard deviation) 28.1 ± 6.2 years) were assessed im-
mediately prior to and during treatment using eight sub-
domains of the NPC clinical severity score (Eye
Movement, Ambulation, Speech, Swallow, Fine Motor
Skills, Cognition, Memory, Seizures).
All patients were on miglustat with the exception of Pa-
tient 1. He had a variable filipin staining pattern, clinically
typical NPC presentation with vertical supranuclear saccade
palsy, cerebellar syndrome, and cognitive impairment.
Moreover, he presented with hebephrenic schizophrenia as
well as major depression with a suicidal attempt. Just one
mutation in exon 6 of the NPC1 gene, c.709 C >T,
p.Pro237Ser has been found. Since both parents have not
been found to be heterozygotes, a de novo mutation in
NPC1 gene is suspected. Due to his genotype, miglustat
was not covered by the health insurance company hence
this patient was not on miglustat therapy unlike the rest of
the study cohort.
During the on-treatment phase NPC patients were
treated with 3 g/day for the first week and 5 g/day of
Acetyl-DL-Leucine (ADLL) (Tanganil, Pierre-Fabre) for
the remaining study duration. This was a compassionate
use observational study. All study participants and/or
guardians of patients gave their informed consent to par-
ticipation in the compassionate use of ADLL.
Results
The demographics of the study cohort are summarised
in Table 1. Data collected comprised total clinical sever-
ity score using the NIH system (see Methods) [12] with
148 measurements in total from 38 patients (minimum
repeat measures per patient = 2, maximum repeat
measures per patient = 9, median repeat measures per
patient = 3) (Table 1). Only patients with complete
sub-score data were included in this study. The two cen-
tres had similar demographics. There was no statistically
significant difference between the age distributions of
the two cohorts (p = 0.36, Wilcoxon-Mann-Whitney
test). The cohort comprised 18 patients with seizures
(38% in Manchester, 52% in Mainz, p = 0.65, χ2 test) and
20 patients without seizures at any point during the
study, including patients with a history of seizures, ef-
fectively managed with anti-seizure medication (Table
1). Total severity measured using the NIH NPC-CSS
[12] at first visit ranged from < 1–33. Patients in Mainz
had higher severity scores relative to Manchester with a
median score of 9 (Manchester) and 15 (Mainz), p = 0.029
(Wilcoxon-Mann-Whitney test). Repeat measurements
spanned 0.94–6.36 years with a median of 4 for Manches-
ter and 3.5 years for Mainz (Table 1). Approximately 95%
of patients were miglustat treated [3] (Table 1). There was
no standardization between centres relating to the stage of
disease when miglustat therapy was initiated or treatment
duration, although dosing was standardized according to
clinical guidelines [15].
NPC patients exhibited differential rates of disease
progression, as previously defined using latent class mix-
ture modelling [10] to detect subpopulations. Although
in common with other LSDs there is a continuum of dif-
ferential rates of disease progression pragmatically, we
have characterised disease progression sub-groups. This
facilitates further analyses and fits well with the objec-
tives of randomised controlled trials where it is essential
to define inclusion/exclusion criteria.
We therefore repeated latent class mixture modelling
on this study cohort by plotting patient age against total
severity score (minus hearing) using the NIH clinical se-
verity scale [12] (Fig. 1). Each patient appears only once,
which was arbitrarily defined as his or her age and sever-
ity score at first visit (Fig. 1a). As defined previously
[10], patients were clustered into six subgroups based on
differential rates of disease progression (Fig. 1a lines
a-f ). The numbers (Fig. 1a) are determined by fitting a
latent class mixture regression model, as detailed in [10].
Arrows show severity progression for each patient from
first to last visit (Fig. 1b). The coloured lines and arrows
represent the different subpopulations (a-f ) determined
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in Fig. 1a to which patients were assigned. This classifi-
cation allocated each patient to the subgroup (a-f ) to
which their initial severity score was closest. Most pa-
tients’ trajectories were well determined by their initial
value and most trajectories followed one of the six sub-
groups defined in our previous analysis [10] (Fig. 1b).
Most of those that deviated moved into the territory of
the next adjacent trajectory. Only one patients changed
classification category by more than one category.
The total severity score is the sum of the neurological
subdomain scores [12] and can be time consuming and
technically challenging to ascertain in standard clinical
settings. We therefore investigated whether one or more
select subdomains could substitute for total severity
score (comprising 8 major and 8 minor subdomains) by
plotting total severity score against individual subdomain
scores and calculating the Spearman’s correlation coeffi-
cient (Fig. 2 (dotted lines corresponding smoothers),
Table 2, Additional file 1: Table S1, Additional file 2:
Table S2 and Additional file 3: Table S3). There was a
significant correlation (p < 0.001) between total severity
scores and single subdomains ranging from 53 to 89% con-
cordance, with the exception of more binary clinical signs
such as e.g. seizures (60%) (Fig. 2 and Additional file 1:
Table S1). We then compared the correlation when we
combined two subdomains (m= 2) with total severity scores.
Correlations rose to range from 71 to 93% (Additional file 2:
Table S2). Combining any three subdomains (m = 3) im-
proved the correlation further (Additional file 3: Table S3)
with correlations ranging from 84 to 96%. As the subdo-
mains we were comparing were contributing to the total se-
verity score we also calculated these correlations excluding
the subdomains we were analysing from the total severity
score. This is summarised in the right-hand column in
Additional file 1: Table S1, Additional file 2: Table S2 and
Additional file 3: Table S3. Removing the subdomains from
the total scores did not greatly affect the correlation coeffi-
cient in most cases. All correlations coefficients shown in
Additional file 1: Table S1, Additional file 2: Table S2
and Additional file 3: Table S3 were highly significant
(p < 0.0001).
In order to understand which of the subdomains relate
most closely to quality of life, sixteen NPC expert clini-
cians and thirty-seven members of patient organisations
(typically parents of affected children and affected
adults) were asked how they valued changes in the major
clinical subdomains, using a simple questionnaire (see
Methods). The data are summarised in Table 3. The
NPC clinical experts selected (in rank order starting with
the most important) the following subdomains; ambulation,
swallowing, speech, cognition and fine motor skills. The pa-
tient organisation members selected ambulation, speech,
Table 1 The demographics of the patients in the two clinical centers are summarized


































Manchester 13 11.16 8 5 12.77 3.92 5 3–9 4.01, 1.05, 6.36 12 (92%) 5 (38.5%)
Mainz 25 12.45 11 14 11.61 16.76 3 2–7 3.50, 0.94, 5.16 24 (96%) 13 (52.0%)
Age in years at first measurement reflects patient age at the first clinical visit included in this study
Fig. 1 Distribution of the study cohort with each patient represented once (first visit) plotting age against unadjusted clinical severity (minus
hearing). a Patients fell into six main subgroups defined by lines a-f (latent class mixture regression model). b The same data are presented colour
coded to lines a-f with arrows showing progression in severity score from first to last visit for each individual in the study
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Fig. 2 Each of the main clinical subdomains (x-axis) were plotted against total severity score and the coefficient of variation (Spearman’s correlation
coefficient) determined (see Additional file 1: Table S1). The dotted line represents the scatterplot’s Friedman’s adaptive smoother. Each patient
appears once. Red dots are patients with seizures
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swallowing, fine motor skills and cognition as the most im-
portant subdomains from their perspective as carers (start-
ing with the most important). The expert physicians and
the parents showed 100% agreement on the five most im-
portant subdomains. The only difference was the relative
rank order of speech and swallowing, with physicians giving
more weight to swallowing than parents/patients.
Neither group weighted seizures as highly important. The
severity of seizures can be confounded by anti-epileptic
medication, which makes it problematic for use as a repre-
sentative subdomain. We therefore compared how well the
five components selected by clinicians and parents/patients
correlated with total severity. This was calculated with and
without inclusion of the components in question in the cal-
culation of the total score. Spearman’s correlation coeffi-
cients were 93% and 71% respectively.
The ASIS score (total severity score/age) was then cal-
culated for all 38 patients at each clinical assessment visit
(Fig. 3a). We found that the majority (82%) of patients had
stable ASIS scores over several years. Stability was defined
by inclusion within the whiskers of the box plot insert
(Fig. 3a). The median ASIS score for the cohort at first
visit was 0.96 (Interquartile range (IQR) = (0.49, 1.52)).
The slopes of individual ASIS scores (box and whisker in-
sert plot) were very close to zero, consistent with a stable
rate of disease progression over the time period measured
(median, 0.004, (IQR = (− 0.0038, 0.094)) (Fig. 3a, inset).
Six outliers had positive rate of change with one outlier
exhibiting a decrease in rate of change. Interestingly, pa-
tients with seizures were over represented in the
non-stable ASIS group (71%) compared to the total cohort
(47%). The patient with the highest score showed a down-
ward slope, reflecting the fact that they had responded to
seizure medication and their severity score/ASIS had de-
clined accordingly.
The patients were then stratified based on whether
they had seizures and their ASIS scores plotted against
time. Patients with lower ASIS values (slower rate of
disease progression) tended to be the patient group not
presenting with seizures (Fig. 3b). The median slope for
the non-seizure group was − 0.003, (IQR = (− 0.03, 0.07))
and for the seizure group (defined as at least one seizure
during the study period) was 0.02, (IQR, − 0.08, 0.19)
(Fig. 3c). The Wilcoxon-Mann-Whitney test comparing
medians was not significantly different (p = 0.74) and the
Ansari-Bradley test for dispersion (spread of data) was
Table 2 Spearman’s pairwise correlations between major subdomains of the Niemann-Pick type C clinical score
Eye movement Ambulation Speech Swallow Fine motor skills Cognition Seizures Memory
Eye movement 1.000 0.600 0.472 0.598 0.606 0.600 0.051 0.509
Ambulation 0.600 1.000 0.679 0.658 0.891 0.810 0.412 0.704
Speech 0.472 0.679 1.000 0.689 0.727 0.728 0.331 0.551
Swallow 0.598 0.658 0.689 1.000 0.754 0.561 0.230 0.485
Fine motor skills 0.606 0.891 0.727 0.754 1.000 0.786 0.430 0.754
Cognition 0.600 0.810 0.728 0.561 0.786 1.000 0.354 0.724
Seizures 0.051 0.412 0.331 0.230 0.430 0.354 1.000 0.366
Memory 0.509 0.704 0.551 0.485 0.754 0.724 0.366 1.000
Table 3 Ranking of clinical subdomains most important to parents of NPC1 patients and expert clinicians. The top 5 subdomains
selected by each group completing the survey are shaded in blue
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not significant (p = 0.09) when comparing the slopes of
ASIS for the seizure/non-seizure groups (Fig. 3d).
To test the potential utility of ASIS for patient recruit-
ment to clinical trials we modelled patient selection for
a hypothetical clinical trial based on our study cohort.
We compared how ASIS scores compared with conven-
tional age/severity score inclusion criteria based on three
real life clinical trials (Fig. 4). The inclusion criteria for
the three trials modelled in this study are those used in
the pivotal miglustat clinical trial (patients older than
12 years [3]) and the current trials for Arimoclomol (age
2–18) (https://clinicaltrials.gov/ct2/show/NCT02612129)
and intra-thecal 2-hydroxypropyl-β-cyclodextrin (age 4
to 21) (https://clinicaltrials.gov/ct2/show/NCT02534844)
(Table 4). All three-age inclusion criteria modelled onto
the study cohort included patients from all severity
groups and included 76.3% (12–60 years inclusion),
57.9% (2–18 years inclusion) and 73.7% (4–21 years in-
clusion) of the study cohort respectively (Fig. 4a-c).
We then modelled patient inclusion solely based on
ASIS. Three different ASIS inclusion criteria thresholds
were applied focusing on ranges that excluded very mild
and very severe patients (0.5 to 2; 0.75 to 2; 1 to 2)
(Fig. 5a1-a3). As predicted, all three ASIS criteria re-
sulted in the inclusion of patients in the middle of the
clinical severity range, eliminating the mild and severe
extremes of the cohort. The percentage of eligible pa-
tients that ASIS defined in our cohort was 63.2%, 50.0%
and 34.2% for ASIS bands of 0.5–2, 0.75–2 or 1–2 re-
spectively. The ASIS score range of 0.5–2.0 (63.2%)
encompassed the broadest range of patients in severity
groups b-d and resulted in the largest group of included
patients (Table 5). The pairwise comparisons of
age-defined and ASIS-defined inclusion are summarised
in Table 5, presented as percentage of patients excluded
and included in between-group comparisons. For ex-
ample, if we compare age inclusion of 4–21 with ASIS
inclusion of 0.5–2, 47.4% of patients would be recruited
to both trials and 10.5% excluded from both trials. We
also modelled ASIS bands with an extended upper limit
from 0.5–2.5, 0.75–2.5 and 1–2.5 (Fig. 5b1-b3). This ex-
panded the percentage of eligible patients slightly to
65.8%, 52.6% and 36.8% respectively. The inclusion of pa-
tients with and without seizures is presented in Fig. 5c.
ASIS bands with lower thresholds encompassed a greater
percentage of non-seizure cases, consistent with the fact
that the non-seizure group tended to have lower ASIS
scores (Fig. 5c and also Fig. 3b). The highest proportion of
patients meeting the inclusion criteria was for ASIS scores
ranging from 0.5–2.5 (65.8%).
Fig. 3 a ASIS scores (total severity/age for every time point) were plotted for each patient over time (years), colour coded to reflect the subgroups
from Fig. 1a. b The same data were plotted colour coding patients with seizures in red. c Box and whisker plots demonstrating the greater variability
of ASIS scores in the seizure versus non-seizure group. d Density plot of ASIS score variation around zero for seizure, non-seizure groups
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In addition to aiding selection of patients for clinical trials,
the other potential application of ASIS is as a prognostic tool.
We therefore modelled predicted (based on ASIS) versus ac-
tual (measured) clinical severity score over time. We com-
pared trajectories of total severity score, minus hearing,
defined from either a single ASIS score (standardised to the
first data point for each patient) or using a mean ASIS score,
taking advantage of repeat measures to see which method
was most robust. We generated four scatterplots represent-
ing patients with and without seizures, and with predicted
trajectories calculated based on a single ASIS determination
at first visit (Fig. 6a (without seizures) and Fig. 6c (with
seizures)) or where predicted trajectories are based on the
average of all available ASIS scores for each patient (Fig. 6b
and d for patients with and without seizures, respectively).
We then fitted individual trajectories defined as straight lines
without intercept and with their slope determined by either
the first value or the mean of all the available ASIS values.
The graph shows the measured points for each individual
over time colour coded to match their predicted trajectories
based on ASIS (single or average). The mean of the max-
imum absolute deviations (MAD) was calculated per individ-
ual in relation to the predicted trajectory, based on a single
or average ASIS score relative to actual severity (a single ex-
ample is shown in Fig. 7a). The goodness-of-fit criterion
(seizure and non-seizure groups combined) based on MAD
indicated that the average ASIS, over all available measure-
ments, had better predictive power (median MAD=2.20,
IQR= (1.10, 4.27) than a single ASIS ascertainment (median
MAD=3.58, IQR= (1.68, 7.62)) (difference between mean
and single ASIS p= 0.027 (Wilcoxon Mann-Whitney), differ-
ence in dispersions (Ansari-Bradley) between mean and sin-
gle was non-significant p= 0.642) (Fig. 7b). When analysing
the non-seizure group based on average ASIS measurements
the value came very close to 1 severity unit (1.28,
IQR = (0.82, 2.27)) (neither location nor dispersion
were significantly different in this group) (Fig. 7c, and
Table 6). Using instead the first available ASIS score the
median of this prediction was higher at 1.73 (IQR = (1.09,
3.90)) (p = 0.086) (Fig. 7c). The seizure group data were
more variable with median ASIS scores giving a higher de-
viation than the non-seizure group in predicted and actual
data, using the average ASIS scores (median MAD= 4.26,
IQR = (2.38, 6.77) (significantly different location p = 0.037,
but not dispersion p = 0.397) and also when using the first
available ASIS score (median MAD= 6.77, IQR = (3.59,
13.96)) (p = 0.037) (Fig. 7d and Table 6). The repeat
Fig. 4 The inclusion criteria for three clinical trials were modeled on
plots of age versus total severity score (minus hearing). a Miglustat
trial, ages > 12; b Arimoclomol trial ages 2–18 and c 2-Hydroxy-beta-
cyclodextrin ages 4–21. The plots depict the study cohort with these
different inclusion criteria indicated with the dotted lines. Included
patients are in black, excluded patients in white
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measures spanned different periods of time for individual
patients. This allowed us to investigate how well ASIS pre-
dicted future clinical severity of patients over three time pe-
riods (up to 2 years, 2–4 years and 4–6 years) (Fig. 7e and f).
Firstly, we investigated how MAD values differed between
predicted and actual scores for patients without seizures
using first or mean ASIS scores (Fig. 7e). The ASIS scores
(when combined and the mean determined) were not signifi-
cantly different over six years (0–2, 2–4 and 4–6 years) rela-
tive to single ASIS determinations (p > 0.073), whereas single
ASIS based predictions were more variable when the same
analysis was performed on patients with seizures (Fig. 7f).
The data were more variable based on single ASIS predic-
tions but mean ASIS scores also gave comparable predictions
over the different time intervals, although at 2–4 years the
single and mean MAD values were significantly differ-
ent (p = 0.003). Taken together these data suggest that
ASIS is a reliable predictor of progression of clinical sever-
ity over a six-year period, particularly if averaged ASIS
scores are used as the basis for the prediction, and that it
is more robust in the non-seizure group i.e. before seizure
onset when there is less phenotypic variability.
ASIS scores were also used to quantify the effect of an
experimental therapy for NPC disease progression using
the modified amino acid Acetyl-DL-Leucine (ADLL).
ADLL has been used (as Tanganil®) in France and selected
former colonies for around 60 years for the treatment of
acute vertigo. A recent publication demonstrated that
short-term (4 weeks) treatment with 5 g/day ADLL was
associated with symptomatic improvement (most notably
in ataxia) in 12 NPC patients [11]. Additionally, the par-
ents/carers of NPC patients anecdotally reported cognitive
improvement on-treatment, suggesting that ADLL may
have clinical benefit beyond amelioration of symptoms of
ataxia [11]. The effect of longer-term ADLL treatment on
disease progression in NPC patients was therefore
assessed (Fig. 8a and b, total severity scores and ASIS on
treatment respectively). Ten NPC patients were treated
with ADLL (5 g/day). The median ages at first visit were
27.3 years (minimum 17, maximum 37.4) for males and
27.7 years (minimum 20, maximum 35.4) for females. At
baseline the median ASIS value was 0.53 (minimum 0.38,
maximum 1.94, mean 0.67). Patients were treated with
ADLL for a median length of 7.7 months (maximum
21.16, minimum 2.7 months). All patients were assessed
at least once during the ‘on-treatment’ period. Six patients
were assessed three times on-treatment, and a further
three were assessed four times on-treatment and one
patient was assessed twice. ASIS at final measurement
ranged from 0.3393 to 1.8526 (median 0.6054, mean 0.473)
(Fig. 8). A linear mixed-effects model fitted with patient iden-
tification as an intercept random effect showed a significant
improvement (reduction) in ASIS on-treatment (p < 0.0001)
(Fig. 8b). On average, ASIS was reduced by an average of
10.4% per year (average rate of change of − 0.06 units per
year), consistent with ADLL slowing the rate of disease pro-
gression in NPC patients. As this was an open-label study a
placebo-controlled trial will be required to determine efficacy
in the future and measurement of ASIS has the potential to
be a useful metric to evaluate in future clinical trials.
Discussion
In rare diseases the combination of low patient numbers
and high degree of clinical heterogeneity makes diagno-
sis, prognosis, clinical monitoring and recruitment to tri-
als challenging. In this study, we have explored the
potential utility of a clinical metric in the rare neurode-
generative lysosomal storage disease, NPC. As NPC cur-
rently has one approved drug (miglustat) and multiple
trials in progress we have focused on this disease to test
and model new methods of patient stratification.
Currently, most clinical monitoring uses non-weighted
severity scales based on multiple neurological subdo-
mains contributing to a total composite severity score.
Conducting these assessments is time-consuming and
technically demanding. As a result, the full composite
clinical score is not routinely ascertained for all patients
in standard clinical settings. Patients with a given clinical
severity score may have radically different ages and dif-
ferent rates of disease progression (Fig. 1). As a result, a
trial based primarily on age inclusion criteria will include
patients spanning the disease spectrum, resulting in a
heterogeneous group that includes the two clinical ex-
tremes. This, in combination with low patient numbers,
poses a significant challenge in proving whether new
therapies are disease modifying or not. This is because the
trial cohort includes patients so mild their clinical score
would not change within the trial period and those with ad-
vanced disease that are less likely to respond to therapy due
to a high burden of pre-existing irreversible pathology.
Table 4 Summary of age inclusion criteria and requirements for neurological signs. The neurological sign requirements are unique
to each clinical study
Trial Selected Inclusion Criteria References/Clinical
Trial IdentifierAge Neurological sign
Miglustat > 12 + [3]
Arimoclomol 2–18 + NCT02612129
2-hydroxypropyl-β-cyclodextrin 2–25 + NCT02534844
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Clinical trial recruitment to date in NPC has been
based on age inclusion criteria, coupled with neuro-
logical signs (reflected by a clinical severity score above
zero), to eliminate the pre-symptomatic patients, but
does not take into account differential rates of disease
progression or achieve any further stratification.
Therefore, to test a new stratification method we have
assembled an international NPC study cohort, based on
patients from two clinical centres in Europe.
We began by investigating whether rate of disease pro-
gression is a more useful metric for stratification for
clinical trials rather than age. In our previous study [10]
Fig. 5 Inclusion criteria based on ASIS scores are plotted using three thresholds (ASIS 0.5 to 2; 0.75 to 2; 1 to 2) plotted in a1-a2 and a3
respectively. The ASIS bands plotted were extended to include 0.5–2.5, 0.75–2.5 and 1–2.5 (b1, b2 and b3 respectively). c The ASIS thresholds
were plotted to demonstrate their influence on seizure/non-seizure cases (non-seizure cases in blue, seizure cases in red)
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we developed a score we termed ASIS that measured the
annual increment in clinical severity for individual pa-
tients. The only data required to calculate ASIS is the
total severity score and the precise age of the patient
when the score was ascertained. It is therefore straight-
forward to calculate on both a retrospective and pro-
spective basis. As long as the clinical scoring system is
consistently applied over time to a given patient it also
does not matter whether it is based on the original NPC
severity score published by Iturriaga and colleagues [16]
or the modified clinical severity score devised by Porter
and colleagues at the NIH [5] or indeed any other scor-
ing system used locally for patient monitoring.
One important finding in this study was that combining
2–3 subdomain scores correlated well with total severity
scores (with and without inclusion of those selected compo-
nents in the total severity score calculation), suggesting that
clinical scoring can be greatly simplified to meet pragmatic
constraints in “real life” clinical settings (Additional file 1:
Table S1, Additional file 2: Table S2 and Additional file 3:
Table S3). It is conceivable that precise single patient
sub-score analyses could reduce some of the measurement
error associated with the composite score. For example, sei-
zures and cognition, being more binary components, can be
confounding in their effects on scores when these domains
are included in the total severity score or combined
subdomain analysis. Even single sub-scores substituted quite
well for total severity scores (Fig. 2 and Additional file
1: Table S1). Based on these findings it may be pos-
sible in the future to have regular testing of one or two
domains in a home setting thus providing more data
points between scheduled clinic visits that often involve
travel and disruption of normal daily routine for patients.
These data also provide insights into the pathogenic
process as they indicate that the various neurological
domains being monitored decline with comparable rates
and progress in parallel. Seizures and memory are out-
liers in this regard. Either other factors contribute to dis-
ease progression in these two domains or, more likely, it
is the binary nature of seizures (and the effect of seizure
medications on seizure scores) and lack of robust ascer-
tainment of declining memory using existing tests that is
responsible for their outlier status.
In our previous study, we observed relative stability of
ASIS in a very small number of individual patients for
whom we had sufficient longitudinal data (10). However,
we lacked statistical power due to a limited period of
time over which patients were longitudinally monitored.
In this study, we therefore collected further longitudinal
data points (repeat measures) on a subset of the patients
from the original study [10]. The striking finding was
that most patients did indeed have relatively stable ASIS
Table 5 Summary of patient’s eligibility to be included (% included) based on different ASIS thresholds compared with three clinical
trials based on age inclusion (upper panel). The lower panel summarise between group comparisons showing the percentage of
patients included and excluded when comparing ASIS inclusion criteria versus age inclusion criteria








Miglustat trial criteria [3] n = 39 > 12 76.3
Vtesse/Sucampo trial criteria n = 44 4–21 73.7
Orphazyme trial criteria n = 39 2–18 57.9
Between groups comparison (% Patients excluded, included)
Age-defined
ASIS-defined > 12 4–21 2–18
0.5–2 15.8, 55.26 10.5, 47.4 10.5, 31.6
0.75–2 15.8, 42.1 18.4, 42.1 21.1, 28.9
1–2 18.4, 28.9 23.7, 31.6 31.6, 23.7
0.5–2.5 13.2, 55.3 10.5, 50.0 10.5, 34.2
0.75–2.5 13.2, 42.1 18.4, 44.7 21.1, 31.6
1–2.5 15.8, 28.9 23.7, 34.21 31.6, 26.3
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scores over time, which suggests that irrespective of
their actual rate of progression an individuals’ rate of
progression remained fairly constant over time. We do
not have sufficient longitudinal data in this study to
determine stability over the lifetime of patients, but that
could readily be collected both retrospectively and pro-
spectively to determine which subset of patients show
changes in rates of clinical progression over time. As
might be anticipated, patients that had progressed to de-
velop seizures were more variable, as they represent a
more severe and advanced phase of the disease, but
many patients with seizures still maintained ASIS score
stability (Fig. 3b). The onset of seizures signals a more
aggressive phase of the disease [5] [6], but as more treat-
ments are introduced it would be anticipated that the
pre-seizure stable ASIS group will expand within the
NPC community (due to slowing of disease progression
in response to combination therapy). One group
underrepresented in this study are adult-onset patients
and we plan more in-depth studies in this subgroup of
patients in the future.
The main aim of the current study was to compare
the potential use of ASIS as a stratification tool for
clinical trial recruitment, relative to standard inclusion
criteria based on age/neurological signs. To make this
more relevant to real-life experience we compared the
inclusion criteria used in one historic study in NPC (piv-
otal miglustat trial, [3]) and two clinical trials in progress
at the time of this study (arimoclomol and intra-thecal
2-hydroxypropyl-β-cyclodextrin). All three studies rely
on patient age as a primary inclusion criterion, coupled
with the need for neurological signs to exclude
pre-symptomatic patients. The inclusion criteria for the
three trials are summarised in Table 4. It is interesting
to note that the neurological inclusion criteria for the
three trials differ and are not comparable in their
Fig. 6 Plots of total severity score minus hearing defined from either a single ASIS score (standardised to the first data point for each patient) or
using a mean ASIS score (repeat measures). The four scatterplots represent patients with and without seizures, and with predicted trajectories
calculated based on a single ASIS determination at first visit (a) (without seizures) and (c) (with seizures)) or where predicted trajectories are
based on the average of all available ASIS scores for each patient (b and d) for patients with and without seizures, respectively. Each patient has
been assigned an individual colour and each visit is represented by a data point (multiple points per patient)
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requirements (NCT02612129, NCT02534844). By defin-
ition ASIS scores report on neurological signs so the
need to specify a particular clinical domain (specific
neurological system affected) is not required, greatly
simplifying and harmonising the inclusion process. Some
specific sub-scores relate more closely to quality of life
(QoL). There was consensus between physicians and pa-
tient family members who identified the five most im-
portant domains as ambulation, swallowing, speech,
cognition and fine motor skills. When combined, these
Fig. 7 The mean of the maximum absolute deviations (MAD) was calculated for each individual in relation to the predicted trajectory, based on a single
or average ASIS score relative to actual severity (panel (a) illustrates MAD in a single case). The black arrow shows the point of maximum deviation. The
goodness-of-fit criterion, based on MAD, is depicted in the box and whisker plots for all patients (b) and patients with no seizures (c) and patients with
seizures panel (d)). The effects of time on MAD determination depicted as box and whisker plots for patients without seizures (e) and with seizures (f). The
analysis was performed for repeat measures spanning data over 0–2 years, 2–4 years and 4–6 years. Each patient only contributes once
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five domains correlated well with total severity, whether
these components contributed to total severity score or
not (correlation coefficients of 0.928 and 0.707 respect-
ively), suggesting they may be the most relevant domains
to analyse in clinical trials with direct QoL relevance.
When the three age-based inclusion criteria were com-
pared (Table 5) the > 12 and 2–18 age inclusion criteria re-
sulted in 76.3% and 57.9% of the cohort being eligible for the
trial respectively, whereas 73.7% were eligible with inclusion
criteria of 4–21 years. What is key to note is that all three
age-based inclusion criteria included patients spanning all
clinical severity groups (Fig. 1a-f). We then compared these
age inclusion criteria with inclusion based solely on ASIS
scores. ASIS resulted in 34–66% eligibility depending on the
stringency of the ASIS score thresholds applied. For example,
ASIS scores between 0.5–2 resulted in 63% of patients being
eligible for inclusion. Applying 0.5–2.5 brings this to 66%.
Taken together, applying ASIS as a recruitment tool does re-
sult in fewer eligible patients than conventional age/clinical
score criteria, but achieves greater clinical homogeneity.
Current clinical trial design for rare diseases is based
on placebo-controlled studies as this has proved to be
most reliable for common disorders. However, this is
challenging in rare diseases due to small patient num-
bers and considerable clinical heterogeneity [17]. Using
patients as their own controls has not yet been incorpo-
rated into the design of most rare disease trials, despite
its potential merit. The results described in this study
suggest that other study designs could be considered.
For diseases such as NPC, where patient-held registries
have recently been created (International Niemann-Pick
Disease Alliance), having a strong body of pre-trial lon-
gitudinal data on individual patients will become a real-
istic prospect for many patients.
Another issue in trial design relates to patient num-
bers needed for these studies. The miglustat study in
NPC was based on pragmatic considerations and no
power calculation was used [3]. Power calculations are
required by regulators but are of questionable value in
rare diseases, as it requires a prediction of effect size to
be made based on minimal/no data. If the effect size is
large enough, efficacy can be demonstrated with min-
imal group sizes (e.g. efficacy was demonstrated based
on spleen and liver volume reductions in trials of en-
zyme replacement therapy (ERT) in a non-comparative
study of 12 Gaucher disease patients [18]). Indeed, a sin-
gle patient would have been a good predictor in this case, as
no known placebo effect could be ascribed to the dramatic
impact of ERT on reducing organomegaly. For trials of dis-
ease modifiers with less dramatic effects, stratifying patients
Table 6 Summary of MAD scores (in clinical severity units) comparing predicted and actual disease progression based on first or
mean ASIS scores for seizure and non-seizure groups
Patient Group First ASIS (severity score units) Mean ASIS (severity score units)
No seizures 1.73 1.28
At least one seizure 6.77 4.26
Fig. 8 a Total Clinical Severity Score and b ASIS scores (total severity score/age at time of assessment) of NPC patients post-commencement of
treatment with 5 g/day Acetyl-DL-Leucine. The initial severity score (and hence ASIS) of one patient was notably higher than that of the other
nine. This patient’s data is therefore provided as a separate graph. Each assessment is represented by one data point
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and combining analysis of pre- and post-treatment for each
patient individually will add greater power, and there will
therefore be less chance of missing disease-modifying effects
of experimental therapies.
The development of more appropriate patient stratifica-
tion techniques for recruitment is key to ensure interpret-
able clinical trial outcomes in the immediate future in rare
disease trials. Based on our findings in this report, ASIS may
greatly facilitate this process by providing an evidence-based
stratification/recruitment tool that is easy to calculate and
apply in any clinical setting. It would also allow patient
stratification in ongoing trials by allowing the identification
of patients at the extremes of the clinical spectrum within
the trial cohort, so the data could be analysed with and with-
out their data in a rational, evidence-based and pre-defined
and justified, way.
In addition to playing a role in patient stratification,
ASIS may also have prognostic value as it should be pos-
sible to determine an individual patient’s ASIS and pre-
dict probable severity score out into the future. This
knowledge would help families plan for the degree and
nature of future disability. When we investigated this in
our study cohort we found that if we took an average
ASIS score based on repeat measurements it compared
well with actual measured severity scores over the time
period of actual clinical measurements (in this case up
to six years). Using a single ASIS determination, as op-
posed to average ASIS, was less accurate but still had
prognostic value. These findings suggest that clinicians,
families and patients can also be better informed about
clinical trial entry decisions, based on more accurate cost:
benefit analysis. For example, if an individual patient is
predicted to have a mild clinical course over many years
they may opt for less invasive trials than patients with a
much more rapidly progressing form of the disease.
It will also be of interest to see if rates of disease pro-
gression in other rare diseases, including other lysosomal
diseases, are as stable over a number of years as they are
in NPC. If that proves to be the case, ASIS may have
broader applicability for stratification, recruitment and
as a potentially prognostic tool. Finally, we demonstrate
the use of ASIS to quantify changes in disease progres-
sion in NPC patients associated with treatment with the
experimental drug ADLL (Fig. 8). The data gathered
over repeat measures over a relatively short time frame
showed a significant reduction of approximately 10% in
the annual rate of disease progression. This observa-
tional study cohort is being followed to generate further
longitudinal data to see if this effect is sustained. A
placebo-controlled trial is needed to determine efficacy
in a rigorous clinical trial setting. ASIS therefore may
also be a useful tool for quantifying the effects of therap-
ies and combination therapies in the future, in both ob-
servational and pivotal clinical trial settings.
Conclusion
We have demonstrated that measuring rate of disease pro-
gression based on ASIS provides a potentially useful tool
for stratifying patents for clinical trials, demonstrating re-
sponse to therapy and as a prognostic indicator. In addition,
we provide evidence that a simplified clinical scoring sys-
tem based on QoL-related clinical sub-domains is robust
and compares well to the full scale that is difficult to ascer-
tain in standard clinical settings. Therefore, taken together
these findings will catalyse improvements in clinical trial
design/recruitment, act as indicators of prognosis and sim-
plify routine clinical assessments.
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